September 8, 2017
This article originally appeared on Poz.
As an alternative to Truvada (tenofovir disoproxil fumarate/emtricitabine) for use as pre-exposure prophylaxis (PrEP) among women at high risk of HIV, the antiretroviral (ARV) Selzentry (maraviroc) is safe and well tolerated, according to a recent study, Healio reports. Researchers behind the Phase II study say advanced research of Selzentry as PrEP is warranted to determine its efficacy in preventing HIV.
The controlled doubled-blind study included 188 HIV-negative women enrolled at one of 12 research sites from the HIV Prevention Trials Network and the AIDS Clinical Trials Group. The women had a median age of 35. Sixty-five percent of them were Black, 17 percent were Latina and 27 percent were white. At enrollment, the women all reported engaging in condomless vaginal or anal sex during the previous 90 days with at least one male partner who was HIV positive or of an unknown HIV status.